REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 133 filers reported holding REATA PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.20 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $1,497,000 | -86.6% | 12,112 | -89.4% | 0.69% | -87.0% |
| Q3 2020 | $11,160,000 | -12.9% | 114,554 | +39.5% | 5.31% | -3.5% |
| Q2 2020 | $12,809,000 | +18.3% | 82,100 | +9.5% | 5.50% | +8.6% |
| Q1 2020 | $10,826,000 | -15.8% | 75,000 | +19.2% | 5.06% | -10.4% |
| Q4 2019 | $12,859,000 | +155.9% | 62,900 | +0.5% | 5.65% | +102.6% |
| Q3 2019 | $5,025,000 | -57.4% | 62,591 | -49.9% | 2.79% | -53.1% |
| Q2 2019 | $11,790,000 | -21.5% | 124,965 | -28.9% | 5.94% | -9.5% |
| Q1 2019 | $15,017,000 | +5.8% | 175,700 | -30.6% | 6.57% | -10.3% |
| Q4 2018 | $14,193,000 | +116.6% | 253,000 | +215.6% | 7.33% | +100.5% |
| Q3 2018 | $6,553,000 | +125.5% | 80,155 | -3.5% | 3.65% | +71.5% |
| Q2 2018 | $2,906,000 | -52.4% | 83,094 | -72.1% | 2.13% | -44.4% |
| Q1 2018 | $6,107,000 | +24.7% | 297,750 | +72.2% | 3.83% | +6.4% |
| Q4 2017 | $4,896,000 | – | 172,897 | – | 3.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |